Skip to main content
Review article

The noncanonical role of EZH2 in cancer

Jinhua HuangCollege of Chemistry and Life Sciences Zhejiang Normal University Jinhua ChinaHongwei GouCollege of Chemistry and Life Sciences Zhejiang Normal University Jinhua ChinaJia YaoCollege of Chemistry and Life Sciences Zhejiang Normal University Jinhua ChinaKaining YiCollege of Chemistry and Life Sciences Zhejiang Normal University Jinhua ChinaZhigang JinCollege of Chemistry and Life Sciences Zhejiang Normal University Jinhua ChinaMasao MatsuokaDepartment of Hematology, Rheumatology, and Infectious Disease Graduate School of Medical Sciences Faculty of Life Sciences Kumamoto University Kumamoto JapanTiejun ZhaoCollege of Chemistry and Life Sciences Zhejiang Normal University Jinhua China
2021en
ABI

Abstract

Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of polycomb repressive complex 2 (PRC2). Dysregulation of EZH2 causes alteration of gene expression and functions, thereby promoting cancer development. The regulatory function of EZH2 varies across different tumor types. The canonical role of EZH2 is gene silencing through catalyzing the trimethylation of lysine 27 of histone H3 (H3K27me3) in a PRC2-dependent manner. Accumulating evidence indicates that EZH2 has an H3K27me3-independent function as a transcriptional coactivator and plays a critical role in cancer initiation, development, and progression. In this review, we summarize the regulation and function of EZH2 and focus on the current understanding of the noncanonical role of EZH2 in cancer.

Identifiers

Citations and references

Cited by 20 references